Candriam Luxembourg S.C.A. raised its holdings in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 10.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 107,000 shares of the company’s stock after buying an additional 10,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.23% of Global Blood Therapeutics worth $4,210,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of GBT. Jane Street Group LLC acquired a new position in Global Blood Therapeutics in the 3rd quarter worth approximately $200,000. Trexquant Investment LP acquired a new position in Global Blood Therapeutics in the 3rd quarter worth approximately $202,000. Dynamic Technology Lab Private Ltd acquired a new position in Global Blood Therapeutics in the 3rd quarter worth approximately $205,000. Virtu KCG Holdings LLC acquired a new position in Global Blood Therapeutics in the 2nd quarter worth approximately $219,000. Finally, Cubist Systematic Strategies LLC boosted its stake in Global Blood Therapeutics by 94.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,205 shares of the company’s stock worth $224,000 after purchasing an additional 3,991 shares during the period. Hedge funds and other institutional investors own 85.95% of the company’s stock.
GBT has been the subject of a number of recent analyst reports. Oppenheimer set a $53.00 price objective on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 23rd. Needham & Company LLC set a $51.00 price objective on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 24th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Global Blood Therapeutics in a research note on Monday, October 23rd. BidaskClub raised shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, November 1st. Finally, SunTrust Banks raised their price objective on shares of Global Blood Therapeutics to $67.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. Two equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $65.80.
Shares of Global Blood Therapeutics Inc (GBT) opened at $62.95 on Friday. Global Blood Therapeutics Inc has a 12-month low of $23.55 and a 12-month high of $65.40. The stock has a market cap of $2,890.00 and a P/E ratio of -24.69.
In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $52.85, for a total value of $158,550.00. Following the completion of the sale, the insider now owns 137,255 shares in the company, valued at approximately $7,253,926.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Peter Radovich sold 812 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $57.30, for a total transaction of $46,527.60. Following the transaction, the insider now owns 6,221 shares in the company, valued at approximately $356,463.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,812 shares of company stock valued at $2,864,728. Insiders own 5.30% of the company’s stock.
WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/17/candriam-luxembourg-s-c-a-raises-position-in-global-blood-therapeutics-inc-gbt.html.
Global Blood Therapeutics Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.